Armeniaspirol C is a minor component of the complex produced by Streptomyces armeiacus, discovered by researchers at Sanofi in 2012. Armeniaspirols are a novel class of antibiotics with a unique chlorinated spiro[4.4]non-8-ene scaffold, potently active against Gram-positive pathogens including MRSA and VRE. The A analogue of Armeniaspirol C is a protonophore disrupting the membrane potential and decreases oxygen consumption in mitochondria. Armeniaspirols inhibits the ATP-dependent proteases ClpXP and ClpYQ in vitro and in the model Gram-positive Bacillus subtilis. The pyrrole chloro group and the methyl group appear to be important for antimicrobial activities.
- Isolation and structural elucidation of armeniaspirols A–C: Potent antibiotics against Gram-positive pathogens. Dufour C. et al. Chem Eur J 2012, 18, 16123.
- Characterization of the biosynthetic gene cluster for the antibiotic armeniaspirols in Streptomyces armeniacus. Qiao Y. et al. J Nat Prod 2019, 82, 318.
- Armeniaspirols inhibit the AAA+ proteases ClpXP and ClpYQ leading to cell division arrest in Gram-positive bacteria. Labana P. et al. Cell Chem Biol 2021, 28, P1703.